BASDAI and ASDAS mean values and SD across the four ASDAS disease activity states in NOR-DMARD (n=310 at 3 months, n=192 at 6 months) and ASSERT (n=219 at 3 and 6 months)
| NOR-DMARD (ASDAS-CRP) | NOR-DMARD (ASDAS-ESR) | ASSERT (ASDAS-CRP) | ||||
|---|---|---|---|---|---|---|
| Disease activity states | BASDAI (mean±SD) | ASDAS (mean±SD) | BASDAI (mean±SD) | ASDAS (mean±SD) | BASDAI (mean±SD) | ASDAS (mean±SD) |
| ASDAS <1.3 (3 months) | 1.09±0.87 | 0.94±0.26 | 1.12±0.79 | 0.92±0.21 | 0.97±0.65 | 0.94±0.22 |
| ASDAS <1.3 (6 months) | 1.01±0.67 | 0.90±0.29 | 1.04±0.73 | 0.91±0.22 | 0.78±0.60 | 0.95±0.20 |
| 1.3≤ASDAS<2.1 (3 months) | 2.17±1.26 | 1.62±0.22 | 2.60±1.30 | 1.66±0.24 | 2.38±0.99 | 1.65±0.23 |
| 1.3≤ASDAS<2.1 (6 months) | 2.37±1.23 | 1.64±0.22 | 2.78±1.15 | 1.67±0.20 | 2.53±1.06 | 1.70±0.24 |
| 2.1≤ASDAS≤3.5 (3 months) | 4.40±1.55 | 2.67±0.38 | 5.29±1.51 | 2.75±0.41 | 4.87±1.55 | 2.78±0.40 |
| 2.1≤ASDAS≤3.5 (6 months) | 4.59±1.73 | 2.75±0.41 | 5.23±1.62 | 2.73±0.42 | 4.92±1.40 | 2.80±0.39 |
| ASDAS>3.5 (3 months) | 6.93±1.33 | 4.12±0.63 | 7.29±1.34 | 4.31±0.62 | 7.07±1.57 | 4.31±0.57 |
| ASDAS>3.5 (6 months) | 7.04±1.42 | 4.23±0.58 | 7.24±1.53 | 4.20±0.52 | 7.19±1.31 | 4.33±0.63 |
ASAS, Assessment of SpondyloArthritis international Society; ASDAS, Ankylosing Spondylitis Disease Activity Score; ASSERT, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; NOR-DMARD, Norwegian register of disease modifying antirheumatic drugs.